Physician profile
Humayon Y Khan
NPI 1609091818
$6,585.88
in general payments reported to CMS, 2019-2025
22 companies · $455 in 2025
The $455 reported for 2025 was more than what 75% of Hospice and Palliative Medicine (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,999 · 2020: $67.59 · 2021: $59.42 · 2022: $333 · 2023: $345 · 2024: $328 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902 · Consulting Fee: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.13 |
| Consulting Fee | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,591.89 | 2019 | |
| Abbvie INC. | $241.64 | 2019-2023 | |
| Mimedx Group, INC. | $225.00 | 2025 | |
| Glaxosmithkline, LLC. | $209.68 | 2023-2025 | Bexsero, Pediarix, Rotarix |
| Exeltis, USA INC. | $209.06 | 2022-2024 | Slynd |
| Myovant Sciences INC. | $185.67 | 2021-2022 | |
| Hologic Sales and Service, LLC | $137.93 | 2019-2023 | Aptima |
| Amarin Pharma, INC. | $124.12 | 2019 | |
| Biogen, INC. | $123.17 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $110.01 | 2019 | |
| Coopersurgical, INC. | $80.55 | 2022-2024 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $68.08 | 2020-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Beigene USA, INC. | $49.02 | 2024 | Brukinsa |
| Dexcom, INC. | $47.47 | 2025 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $38.78 | 2023-2024 | Twirla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $28.02 | 2023 | Perclot |
| Bayer Healthcare Pharmaceuticals INC. | $27.40 | 2019 | |
| Organon LLC | $22.05 | 2024 | |
| Pfizer INC. | $19.95 | 2024 | |
| Sanofi Pasteur INC. | $18.15 | 2025 | |
| Roche Diagnostics Corporation | $14.30 | 2019 | |
| Smith+Nephew, INC. | $13.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humayon Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.